Kenneth Janzon
Chief Tech/Sci/R&D Officer at Nordvacc Läkemedel AB
Net worth: 396 723 $ as of 2024-03-30
Profile
Kenneth Janzon is the founder of Intervacc AB, which was founded in 2001.
He held the title of Independent Director at Intervacc AB.
Currently, Mr. Janzon is the Chief Technical Officer at Nordvacc Läkemedel AB.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INTERVACC AB
1.51% | 2023-06-29 | 1,146,500 ( 1.51% ) | 396 723 $ | 2024-03-30 |
Kenneth Janzon active positions
| Companies | Position | Start |
|---|---|---|
Nordvacc Läkemedel AB
 Nordvacc Läkemedel AB Medical DistributorsDistribution Services Part of Intervacc AB, Nordvacc Läkemedel AB is a veterinary pharmaceutical company based in Hägersten, SE. Nordvacc Läkemedel AB was acquired by Sorkaruga AB on March 25, 2014. The Swedish company specializes in the distribution and marketing of veterinary vaccines and medicines for the care and treatment of both companion and farm animals. The private company's flagship product, infucal® vet, is a solution for calving paralysis and is vital for the survival of cattle. The product contains calcium, magnesium, a source of phosphorus in the form of sodium hypophosphite, and glucose, which counteracts hypomagnesemia and is used to treat other conditions with hypocalcemia in animals. The CEO of the company is Rune Bergman. | Chief Tech/Sci/R&D Officer | - |
Former positions of Kenneth Janzon
| Companies | Position | End |
|---|---|---|
| INTERVACC AB | Founder | 2018-06-13 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| INTERVACC AB | Health Technology |
| Private companies | 1 |
|---|---|
Nordvacc Läkemedel AB
Nordvacc Läkemedel AB Medical DistributorsDistribution Services Part of Intervacc AB, Nordvacc Läkemedel AB is a veterinary pharmaceutical company based in Hägersten, SE. Nordvacc Läkemedel AB was acquired by Sorkaruga AB on March 25, 2014. The Swedish company specializes in the distribution and marketing of veterinary vaccines and medicines for the care and treatment of both companion and farm animals. The private company's flagship product, infucal® vet, is a solution for calving paralysis and is vital for the survival of cattle. The product contains calcium, magnesium, a source of phosphorus in the form of sodium hypophosphite, and glucose, which counteracts hypomagnesemia and is used to treat other conditions with hypocalcemia in animals. The CEO of the company is Rune Bergman. | Distribution Services |
- Stock Market
- Insiders
- Kenneth Janzon
